Form 4: Inari Medical CEO Andrew Hykes Sells Shares Under 10b5-1 Trading Plan
SEC Form 4
Inari Medical's CEO, Andrew Hykes, sold 3,000 shares of common stock at $50 per share under a pre-arranged 10b5-1 trading plan.
Summary
- Andrew Hykes, the President and CEO of Inari Medical, Inc., sold 3,000 shares of common stock on August 20, 2024.
- The sale was executed at a price of $50 per share.
- This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2023.
- Following the transaction, Hykes directly owns 452,532 shares of Inari Medical common stock.
- Hykes also indirectly owns shares through his spouse (1,000 shares) and three children (1,550 shares each).
- 280 shares were acquired on July 31, 2024 through the Issuer's Employee Stock Purchase Program.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock transactions by an insider. It doesn't inherently convey positive or negative sentiment.
Industry Context
Sales by company executives are a normal part of corporate governance. The use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on inside information.
Stakeholder Impact
- The sale of shares by the CEO could be perceived negatively by some shareholders, although the use of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 2023-11-13 | Date of adoption of Rule 10b5-1 trading plan. |
| 2024-07-31 | Date of acquisition of 280 shares through the Employee Stock Purchase Program. |
| 2024-08-20 | Date of stock sale transaction. |
| 2024-08-22 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.